For informational and research purposes only.
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Find a topic you’re curious about and take a closer look.
Maca’s small trials sometimes report sexual symptom benefits without testosterone changes. Learn what improved, what did not and why the distinction matters.
Read articleThymosin beta-4 has shown different effects across cancer models. Learn what overexpression, cell-exposure and mouse studies can say about human safety.
Read articleKisspeptin studies use brain scans to explore sexual responses. Learn what BOLD imaging adds, how the trials worked and why lasting benefit is a separate question.
Read articleResearch schedules help identify a treatment worth testing further. They don't establish a personal starting dose, conversion or combination protocol.
Read articleSeparate CJC-1295 exposure from GH secretion and IGF-1 response, including the human pulse study and the limits of timing-based treatment claims.
Read articleThe diabetes trial planned HbA1c as a primary outcome. Its small changes, lipid findings and follow-up still leave important treatment questions open.
Read articleA closer look at the people, placebo comparisons and sleep measurements behind the conflicting older DSIP reports.
Read articleWhat scalp EEG, deep-sleep staging and a small anaesthesia experiment can tell us about DSIP and restorative sleep.
Read articleDifferent obesity and aging studies report different MOTS-c patterns. Population, tissue, timing, units and assay methods explain why comparisons need care.
Read articleWhat KPV's intestinal and skin research shows, how the K(D)PT trial differs, and which patient questions remain after the 2026 discussion.
Read articleTea, extract capsules and inhaled chamomile oil have been tested in different people with different controls. Here is what their sleep findings mean.
Read articleRat metabolites, horse detection studies, and human thymosin beta-4 trials answer different questions. None supplies a dosing timetable for the TB-500 fragment.
Read article518–529 of 600 articles
